Evaluation of the efficacy and safety for switching from premixed insulin to ultra-long acting insulin plus ultra-rapid insuli
Not Applicable
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000009562
- Lead Sponsor
- Department of Endocrinology and Metabolism, Nagoya City West Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1.patients who need insulin therapy newly during this study 2.patients who have allergy for insulin glargine or glulisine 3.patients who had suffered from severe ketosis and diabetic coma or pre-coma 4.patients with serious infection, inflammation, or injury pre- or post- operative state 5.patients who are pregnant, hope to be pregnant, or are in lactation period 6.patients had suffered from drug-induced muscle disorder 7.drug abuser or heavy alcohol drinker
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decrease in HbA1c level Decrease in casual blood glucose level
- Secondary Outcome Measures
Name Time Method Frequency of hypoglycemia Frequency of hyperglycemia Change in body weight Change in convenience to switch to ultra-long acting insulin plus ultra-rapid insulin